

Code	Code Description	Z1 Fee on File Medicaid Rate				O1 Outpatient Hospital Rate			
		Begin Date	Fee	Minimum Age	Maximum Age	Begin Date	Fee	Minimum Age	Maximum Age
0001A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, MRNA-LNP, SPIKE PROTEIN, PRESERVATIVE FREE, 30 MCG/0.3ML DOSAGE, DILUENT RECONSTITUTED; FIRST DOSE	Effective Begin Date 3/15/2	\$35.87	12	999	Effective Begin Date 2/1/2021	\$15.50	12	999
0002A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, MRNA-LNP, SPIKE PROTEIN, PRESERVATIVE FREE, 30 MCG/0.3ML DOSAGE, DILUENT RECONSTITUTED; SECOND DOSE	Effective Begin Date 3/15/2021	\$35.87	12	999	Effective Begin Date 2/1/2021	\$25.50	12	999
0003A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, MRNA-LNP, SPIKE PROTEIN, PRESERVATIVE FREE, 30 MCG/0.3 ML DOSAGE, DILUENT RECONSTITUTED; THIRD DOSE	Effective Begin Date 8/12/2021	\$35.87	12	999	Effective Begin Date 8/12/2021	\$31.26	12	999
0004A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, MRNA-LNP, SPIKE PROTEIN, PRESERVATIVE FREE, 30 MCG/0.3 ML DOSAGE, DILUENT RECONSTITUTED; BOOSTER DOSE	Effective Begin Date 9/22/2021	\$35.87	18	999	Effective Begin Date 9/22/2021	\$31.26	18	999
0011A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, MRNA-LNP, SPIKE PROTEIN, PRESERVATIVE FREE, 100 MCG/0.5ML DOSAGE; FIRST DOSE	Effective Begin Date 3/15/2021	\$35.87	18	999	Effective Begin Date 2/1/2021	\$15.50	18	999
0012A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, MRNA-LNP, SPIKE PROTEIN, PRESERVATIVE FREE, 100 MCG/0.5ML DOSAGE; SECOND DOSE	Effective Begin Date 3/15/2021	\$35.87	18	999	Effective Begin Date 2/1/2021	\$25.50	18	999
0013A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, MRNA-LNP, SPIKE PROTEIN, PRESERVATIVE FREE, 100 MCG/0.5 ML DOSAGE; THIRD DOSE	Effective Begin Date 8/12/2021	\$35.87	18	999	Effective Begin Date 8/12/2021	\$31.26	18	999
0031A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, DNA, SPIKE PROTEIN, ADENOVIRUS TYPE 26 (AD26) VECTOR, PRESERVATIVE FREE, 5x10^10 VIRAL PARTICLES/0.5ML DOSAGE, SINGLE DOSE	Effective Begin Date 3/15/2021	\$35.87	18	999	Effective Begin Date 2/27/2021	\$28.89	18	999
0034A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, DNA, SPIKE PROTEIN, ADENOVIRUS TYPE 26 (AD26) VECTOR, PRESERVATIVE FREE, 5X1010 VIRAL PARTICLES/0.5ML DOSAGE; BOOSTER	Effective Begin Date 10/20/2021	\$35.87	18	999	Effective Begin Date 10/20/2021	\$31.26	18	999

0064A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, RECOMBINANT SPIKE PROTEIN NANOPARTICLE, SAPONIN-BASED ADJUVANT, PRESERVATIVE FREE, 5 MCG/0.5ML DOSAGE; BOOSTER	Effective Begin Date 10/20/2021	\$35.87	18	999	Effective Begin Date 10/20/2021	\$31.26	18	999
0071A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, MRNA-LNP, SPIKE PROTEIN, PRESERVATIVE FREE, 10 MCG/0.2 ML DOSAGE, DILUENT RECONSTITUTED, TRIS-SUCROSE FORMULATION; FIRST DOSE	Effective Begin Date 10/29/2021	\$35.87	5	11	Effective Begin Date 10/29/2021	\$31.26	5	11
0072A	IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]) VACCINE, MRNA-LNP, SPIKE PROTEIN, PRESERVATIVE FREE, 10 MCG/0.2 ML DOSAGE, DILUENT RECONSTITUTED, TRIS-SUCROSE FORMULATION; SECOND DOSE	Effective Begin Date 10/29/2021	\$35.87	5	11	Effective Begin Date 10/29/2021	\$31.29	5	11
M0240	INTRAVENOUS INFUSION OR SUBCUTANEOUS INJECTION, CASIRIVIMAB AND IMDEVIMAB INCLUDES INFUSION OR INJECTION, AND POST ADMINISTRATION MONITORING, SUBSEQUENT REPEAT DOSES	Effective Begin Date 7/30/2021	\$343.60	12	999	Effective Begin Date 7/30/2021	\$343.60	12	999
M0243	INTRAVENOUS INFUSION, CASIRIVIMAB AND IMDEVIMAB INCLUDES INFUSION AND POST ADMINISTRATION MONITORING	Effective Begin Date 11/21/2020	\$237.50	12	999	Effective Begin Date 2/1/2021	\$242.88	12	999
M0245	INTRAVENOUS INFUSION, BAMLANIVIMAB AND ETESEVIMAB, INCLUDES INFUSION AND POST ADMINISTRATION MONITORING	Effective Begin Date 2/9/2021	\$237.50	12	999	Effective Begin Date 4/1/2021	\$242.88	12	999
M0249	INTRAVENOUS INFUSION, TOCILIZUMAB, FOR HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (2 YEARS OF AGE AND OLDER) WITH COVID-19 WHO ARE RECEIVING SYSTEMIC CORTICOSTEROIDS AND REQUIRE SUPPLEMENTAL OXYGEN, NON-INVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) ONLY, INCLUDES INFUSION AND POST ADMINISTRATION MONITORING, FIRST DOSE	Effective Begin Date 6/24/2021	\$343.60	2	999	Effective Begin Date 6/24/2021	\$343.60	2	999
M0250	INTRAVENOUS INFUSION, TOCILIZUMAB, FOR HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (2 YEARS OF AGE AND OLDER) WITH COVID-19 WHO ARE RECEIVING SYSTEMIC CORTICOSTEROIDS AND REQUIRE SUPPLEMENTAL OXYGEN, NON-INVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) ONLY, INCLUDES INFUSION AND POST ADMINISTRATION MONITORING, SECOND DOSE	Effective Begin Date 6/24/2021	\$349.00	2	999	Effective Begin Date 6/24/2021	\$349.00	2	999